Canada approves Eli Lilly's oral GLP-1 weight-loss pill Foundayo
Solo los hechos

Canada approves Eli Lilly's oral GLP-1 weight-loss pill Foundayo

Resumen

Health Canada authorized Eli Lilly's once-daily oral GLP-1 medication Foundayo for obesity and type-2 diabetes, adding a new pill option alongside existing injectables.

Health Canada gave approval to Eli Lilly's oral GLP-1 medication Foundayo for adults with obesity or overweight individuals with related health conditions, such as high blood pressure or sleep apnea. The pill is also cleared for use in type-2 diabetes treatment.

The approval follows Eli Lilly's earlier success with injectable GLP-1 drugs Zepbound and Mounjaro, and introduces a non-peptide GLP-1 receptor agonist, orforglipron, that can be taken once a day.

"Choice is good, and the more options that we have, the more any particular person can find the thing that works for them," said Dr. Hertzel Gerstein, professor of medicine at McMaster University and Hamilton Health Sciences.

Eli Lilly expects Foundayo to reach pharmacies in January, while a competing oral formulation from Novo Nordisk, a Wegovy pill, is still pending Canadian approval. Both oral products are already available in the United States.

The main practical difference between oral and injectable GLP-1 therapies is dosing frequency. Injectables such as Zepbound are administered weekly, whereas oral options like Foundayo and Rybelsus are taken daily. Clinicians may choose the form that best fits a patient’s adherence preferences.

"You treat a patient, not a disease," Gerstein added. "Some people would prefer the injection once a week and then forget about it. Some people will prefer the pill."

Foundayo can be taken with or without food, unlike semaglutide-based oral pills that require an empty stomach. This flexibility may simplify daily routines for some users.

Cost considerations vary: without insurance, weekly Zepbound injections range from CAD $275 to $650, Wegovy injections from CAD $400 to $570, and a 30-day supply of Rybelsus costs just over CAD $300. In the United States, Foundayo lists at US $650 per month without insurance.

Clinical trials show comparable efficacy across forms. Participants on the Wegovy oral pill lost about 13.6% of body weight over 71 weeks, while the injectable achieved roughly 15% loss. For Foundayo, the highest oral dose produced about 12% weight loss over 72 weeks, compared with 15-20% for Eli Lilly's injectables.

Both oral and injectable GLP-1 drugs share similar gastrointestinal side effects, such as nausea and vomiting.

"Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath," the company warned.

A recent Lancet Regional Health Europe study linked GLP-1 weight-loss medications used for type-2 diabetes to a doubled risk of heart attack, stroke or death, underscoring the need for medical supervision.

"Make sure you’re reaching out to your family, doctor, nurse practitioner or pharmacist to ask about how can I see what the lowest dose possible is for me," advised pharmacist Jennifer Lake.

Sigue leyendo, gratis

Crea una cuenta gratis para seguir las noticias. No se requiere tarjeta.